



ASX / MEDIA RELEASE

11<sup>th</sup> July 2016

## Worldwide Full Year Dose Sales Growth of 16.4%

**Sydney, Australia; 11<sup>th</sup> July 2016** – Sirtex Medical Limited (ASX:SRX) is pleased to announce that unaudited worldwide dose sales of SIR-Spheres<sup>®</sup> Y-90 resin microspheres for the 12 months ended 30<sup>th</sup> June 2016 increased 16.4% over the prior corresponding period (pcp). The growth delivered was at the upper end of the 15-17% dose sales guidance provided on the 1<sup>st</sup> of June. The Americas recorded second half and full year dose sales growth of 19.2% and 19.0%, respectively; also within previous guidance. EMEA recorded full year dose sales growth of 11.2% and APAC showed growth of 8.9% over the pcp.

Mr Gilman Wong, Chief Executive Officer of Sirtex Medical commented “The strong double digit growth in global dose sales reflects the continued momentum we have achieved in this large, under-penetrated market opportunity for SIR-Spheres microspheres.”

Sirtex will report its 2016 financial year results on the 24<sup>th</sup> of August, 2016.

### About SIR-Spheres<sup>®</sup> Y-90 Resin Microspheres

SIR-Spheres Y-90 resin microspheres are a medical device used in interventional oncology and delivered via Selective Internal Radiation Therapy (SIRT), also known as radioembolisation, directly to liver tumours. SIR-Spheres Y-90 resin microspheres are approved for supply in key markets, such as the United States, European Union and Australia.

### About Sirtex Medical

Sirtex Medical Limited (ASX:SRX) is an Australian-based global healthcare business working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer. Approximately 61,000 doses have been supplied to treat patients with liver cancer at more than 950 medical centres in over 40 countries. For more information please visit [www.sirtex.com](http://www.sirtex.com).

For further information please contact:

### Investor Enquiries:

Mr Gilman Wong  
CEO  
Sirtex Medical Limited  
Phone: +61 (0) 2 9964 8400

Dr Tom Duthy  
Global Investor Relations Manager  
Sirtex Medical Limited  
Phone: +61 (0) 2 9964 8427  
Email: [tduthy@sirtex.com](mailto:tduthy@sirtex.com)

SIR-Spheres<sup>®</sup> is a registered trademark of Sirtex SIR-Spheres Pty Ltd

---

**Head Office**  
Level 33, 101 Miller Street  
North Sydney, NSW 2060  
Australia

**Americas**  
300 Unicorn Park Drive  
Woburn, MA 01801  
United States

**Europe, Middle East & Africa**  
Josef-Schumpeter-Allee 33  
53227 Bonn  
Germany

**Asia Pacific**  
50 Science Park Road, #01-01  
The Kendall Science Park II  
Singapore 117406